← All trials
NCT07234474
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2026
- Primary completion
- Nov 30, 2027
- Completion date
- Feb 29, 2028
- First posted
- Nov 18, 2025
- Last posted
- Nov 18, 2025
- Enrollment
- 66
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Excyte Biopharma LtdLead sponsor
- Peking UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.